Investment Rating - The report maintains an "OUTPERFORM" rating for the company with a target price of HKD 464.20, up from a previous target of HKD 269.70 [2][21]. Core Insights - The company's "ADC+IO" strategy is progressing steadily, with early-stage molecules expected to demonstrate their potential [1][5]. - The company reported a revenue of RMB 1.23 billion for 1H25, representing a growth of 22.9%, primarily driven by licensing and collaboration income [3][16]. - The company has a strong cash position of RMB 3.75 billion, which is sufficient to support its clinical and early-stage R&D investments for the next 3-5 years [4][17]. Financial Performance - Revenue projections for 2025-2027 are estimated at RMB 1.75 billion, RMB 0.97 billion, and RMB 1.37 billion, respectively, with year-on-year growth rates of -10%, -44%, and +41% [10][21]. - The company recorded a net loss of RMB 2.08 billion in 1H25, with an adjusted net profit of RMB 150 million after excluding fair value changes of preferred shares [3][16]. - The gross profit margin is projected to decline from 76.1% in FY2023 to -19.2% in FY2026 [14][15]. Pipeline and Collaborations - The company is advancing three ADC programs in collaboration with BioNTech, which are currently in Phase I/II clinical trials [5][18]. - The DB-1303 (HER2 ADC) is expected to file for FDA BLA for endometrial cancer and NDA submission in China for HER2+ breast cancer in 2H25 [20]. - The newly disclosed DB-1317 (ADAM9 ADC) is about to enter Phase I trials, showing an ~80% response rate in preclinical models [19][20]. Valuation - The company is valued using a DCF model based on FY26-34 cash flows, applying a WACC of 10.0% and a terminal growth rate of 3.5% [10][21]. - The revised target price of HKD 464.20 reflects the company's potential for future royalty income from BioNTech [21].
映恩生物-B（09606）：“ADC+IO”战略稳步推进，早期分子有望展露潜力